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SenescenceThe inositol 1,4,5-trisphosphate (IP3) receptor (IP3R) type 2 (IP3R2) is an intracellular Ca2+-release channel
located on the endoplasmic reticulum (ER). IP3R2 is characterized by a high sensitivity to both IP3 and ATP and
is biphasically regulated by Ca2+. Furthermore, IP3R2 is modulated by various protein kinases. In addition to its
regulation by protein kinase A, IP3R2 forms a complex with adenylate cyclase 6 and is directly regulated by
cAMP. Finally, in the ER, IP3R2 is less mobile than the other IP3R isoforms, while its functional properties appear
dominant in heterotetramers. These properties make the IP3R2 a Ca
2+ channel with exquisite properties for set-
ting up intracellular Ca2+ signalswith unique characteristics. IP3R2 plays a crucial role in the function of secretory
cell types (e.g. pancreatic acinar cells, hepatocytes, salivary gland, eccrine sweat gland). In cardiac myocytes, the
role of IP3R2 appearsmore complex, because, togetherwith IP3R1, it is needed for normal cardiogenesis, while its
aberrant activity is implicated in cardiac hypertrophy and arrhythmias. Most importantly, its high sensitivity to
IP3makes IP3R2 a target for anti-apoptotic proteins (e.g. Bcl-2) in B-cell cancers. Disrupting IP3R/Bcl-2 interaction
therefore leads in those cells to increased Ca2+ release and apoptosis. Intriguingly, IP3R2 is not only implicated in
apoptosis but also in the induction of senescence, another tumour-suppressive mechanism. These results were
the ﬁrst to unravel the physiological and pathophysiological role of IP3R2 andwe anticipate that further progress
will soon be made in understanding the function of IP3R2 in various tissues and organs.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
The inositol 1,4,5-trisphosphate (IP3) receptors (IP3Rs) are ubiqui-
tously expressed intracellular Ca2+-release channels. These channels
are tetrameric in structure and predominantly localized in the endo-
plasmic reticulum (ER). IP3, produced by phospholipase C after cell
activation by hormones, growth factors or neurotransmitters, diffuses
into the cytosol, binds to and activates the IP3R, leading to Ca2+ release
from the ER. This Ca2+ release is instrumental in the formation of the, ProteinkinaseB;ANF,Atrialna-
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).spatio-temporal Ca2+ signals, fundamental for the regulation of multi-
ple cellular processes, including proliferation, differentiation, metabo-
lism, secretion, cell fate and memory [1–3].
In all vertebrate organisms, three different genes encode IP3Rs, lead-
ing to three main types of IP3Rs, IP3R1 (ﬁrst fully cloned in 1989 [4]),
IP3R2 (ﬁrst fully cloned in 1991 [5]) and IP3R3 (ﬁrst fully cloned in
1993 [6]). Each monomer is about 2700 amino acids in length and
consequently has a predicted molecular mass of approximately
300 kDa. The IP3R proteins are structurally and functionally divided
into 5 distinct domains: the N-terminal coupling domain (a.k.a. sup-
pressor domain), the IP3-binding core, the internal coupling domain
(a.k.a the modulatory and transducing domain), the channel domain
and the C-terminal coupling domain (a.k.a. the gatekeeper domain)
[7]. The three IP3R isoforms share only 60–80% overall similarity at the
amino acid level, but the similarity is much higher in certain deﬁned re-
gions (e.g. the IP3-binding site, the 5th and 6th transmembrane regions,
putative ER-retention signals) while much lower in others, allowing for
the existence of very distinct properties between the isoforms (see
Section 2). Finally, a further diversity can result from alternative splicing
and the formation of heterotetramers [1,8,9].
The vast majority of cell types express more than one IP3R isoform
but their relative proportion can be highly variable [10–14]. Moreover,
in various cases it was shown that the relative expression levels
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could be modulated by speciﬁc treatments (e.g. [14–21]).
The participation of the IP3Rs in establishing distinct patterns of
Ca2+ signals resulting in different cellular outcomes depends therefore
on the complement of the various IP3R (splice) isoforms expressed,
their intracellular location, the presence of regulatory factors, including
associated proteins, and their phosphorylation status [1,14,22–25].
On the basis of their almost exclusive expression of a single IP3R
isoform, some cell types have been used as model system for the
analysis of the role of the different IP3R isoforms [8]. However, only a
rather limited set of cell types expresses predominantly IP3R2 (Table 1).
Interestingly, inmany cells IP3R2 is expressed at a different subcellu-
lar location than the other IP3R isoforms. For example, in bovine aortic
endothelial cells, bovine adrenal glomerulosa cells and COS-7 cells
[26], the HepG2 liver cell line [27] and the hippocampal cell line HT22
[28] IP3R2 displayed a predominantly nuclear localization, while in
hepatocytes IP3R2 is conﬁned to the apical pole of the cell, near the
canalicular membrane [29].
The nuclear localization of IP3R2 is particularly interesting with re-
spect to the role of Ca2+ signalling in the nucleus, e.g. for gene transcrip-
tion. Although the presence of IP3Rs in the inner leaﬂet of the nuclear
envelope remains the subject of debate [30–32], there is at least strong
evidence that a subset of the IP3R2 is facing the nucleoplasm in HepG2
cells [27], in SKHep1 cells [33] and in atrial myocytes [34] where they
can control Ca2+ release directly into the nucleus.
Information concerning the regulation of IP3R2 expression is like-
wise still quite limited. The 5’-ﬂanking region of murine IP3R2 has
been sequenced and contained at least 7 transcription initiation sites
with an upstream promoter containing no conventional TATA box but
a GC box [35]. To the best of our knowledge, only two recent studies de-
scribed pathways involved in the regulation of IP3R2 expression. First, in
the heart, direct binding of nuclear factor of activated T cells (NFAT) c1
to the IP3R2 promoter drives IP3R2 expression [36]. Second, in dendritic
cells, IP3R2 expression is controlled by the transcription factor ETS1,
which itself depends on protein kinase B (AKT/PKB) 2 [37]. Finally,
although not yet understood at the mechanistic level, in the HT22 cell
line, oxidative stress leads to a speciﬁc upregulation of IP3R2 [38]
(see Section 5).
Splicing of IP3R2 is much less documented than that of IP3R1, but
two different splice variants have been described. One appears to be
muscle-speciﬁc and is limited to the N-terminal 175 amino acids of
IP3R2 supplemented with 6 additional amino acids; although a regula-
tory role has been proposed, its function has not yet been elucidated.
[39]. The second splice variant uses the same splice acceptor site and
is lacking amino acids 176-208. The deletion is localized fully within
the suppressor domain, which plays an important role in both the regu-
lation of IP3 binding and in the coupling of the IP3R N-terminus to the
channel region [40]. As a consequence, the resulting protein is defective
in both IP3 binding and Ca2+ release. However, its expression in cells
prevents the agonist-dependent clustering of the endogenous IP3Rs,
probably via heterotetramerization, and can therefore impact intracel-
lular Ca2+ signalling [41].Table 1
Cell types or tissues predominantly expressing IP3R2.
Cell type/tissues Relevant references Speciﬁc remarks
(in alphabetical order)
AR42J [11,12] Pancreatoma cell line
Cardiac myocytes [12,13,136,189]
Glia [117,190]
Hepatocytes [11–13,29] Polarized expression IP3R2
Intercalated cells of
renal collecting duct
[191]
Pancreatic acinar cells [12] IP3R3≈ IP3R2
RBL-2H3 [11,115,192] Mucosal mast cell lineFinally, also at the protein level, IP3R2 levels appear to be regulat-
ed in a different manner when compared to the other isoforms.
While all IP3R isoforms are downregulated under conditions of
chronic stimulation [12,42,43], IP3R2 appeared the least susceptible
[12].
In spite of the unique molecular properties displayed by IP3R2 (see
Sections 2.1–2.5), this protein is much less investigated than IP3R1 or
indeed, even IP3R3. This apparent lack of progress was probably in
retrospect multifaceted. The low general abundance of IP3R2 and the
lack of good model systems for its investigation partially explain the
fewer studies directed speciﬁcally towards the IP3R2. Additionally, but
no less importantly, it appeared that it was historically difﬁcult to
make IP3R2 expression constructs.Moreover, the quality of the antibod-
ies raised against IP3R2was also generally poor. Finally, a recent analysis
of classically used IP3R inhibitors demonstrated that IP3R2 expressed
in DT40 triple knockout (DT40 TKO) chicken B lymphocytes was the
least sensitive of all the IP3R isoforms to heparin, caffeine and
2-aminoethoxydiphenyl borate [44]. This latter observation may
explain why pharmacological approaches to discern IP3R2 function
have been largely unsuccessful.
Notwithstanding these issues, recent work has begun to unravel the
signiﬁcance of IP3R2 in a number of physiological settings. The aim of
this review is therefore to highlight these important functions of IP3R2
and to so stimulate further research in the ﬁeld.
2. Speciﬁc molecular and cellular properties of IP3R2
IP3R2 has a high sequence and structural homology with the other
IP3R isoforms and consequently shares a large number of properties
with IP3R1 and IP3R3. In this chapter, we will therefore focus on speciﬁc
properties in which the IP3R2 clearly differs from the other isoforms
(Fig. 1).
2.1. IP3 afﬁnity
Binding of IP3 to the IP3-binding core is the key step needed for
the induction of IP3-induced Ca2+ release. As stated above (see
Section 1), the three IP3R isoforms all have a very similar struc-
ture [45]. For example, all IP3R isoforms contain their IP3-binding
core towards their N-terminus, preceded by the so-called suppressor
domain [46].
A striking property of the IP3R2 is its much higher afﬁnity for IP3
when compared with the two other IP3R isoforms. This was ﬁrst
observed in IP3-binding experiments, which under various conditions
demonstrated a rank-order of IP3 afﬁnities IP3R2 N IP3R1 N IP3R3 [5,10,
47]. Subsequent studies conclusively demonstrated that the IP3-
binding cores of each of the IP3R isoforms display a similar afﬁnity for
IP3 (about 2 nM), but as demonstrated by the analysis of normal and
chimeric N-terminal domains of the different IP3R isoforms the pres-
ence of the suppressor domain determines the speciﬁc IP3 afﬁnity of
the isoform (50, 14 and 163 nM for IP3R1, IP3R2 and IP3R3, respectively).
These results underpin the importance of the suppressor domain for
IP3R function [46].
The difference in IP3 afﬁnity is also reﬂected in functional experi-
ments. Analysis of IP3-induced Ca2+ release in DT40 TKO cells express-
ing a single IP3R isoform demonstrated that DT40 TKO cells
heterologously expressing a single IP3R isoform could sustain Ca2+
oscillations for an extended period after stimulation by an anti B-cell
receptor antibody only if the expressed isoform was IP3R2 [48]. Very
similar results were obtained in vascular myocytes, whereby only the
cells expressing IP3R2 in addition to IP3R1 displayed a Ca2+ oscillation
pattern [49,50]. Comparison of native IP3R1 (from cerebellum) and
IP3R2 (from heart) [51] or the comparative analysis of each of the
three IP3R isoforms heterologously expressed in Sf9 insect cells [52]
also conﬁrmed the rank-order of the sensitivity of channel opening
Fig. 1. Linear representation of the IP3R2 based on the human sequence demonstrating the interaction sites for its major regulators. The IP3R2 is represented in blue; the 5 functional
domains are indicated. In the channel domain, the 6 transmembrane helices as well as the connecting loops are depicted in green. The speciﬁc regulatory mechanisms discussed in the
text are shown: identiﬁed phosphorylation sites are represented in dark blue, interaction sites for ATP and for Bcl-2 are in orange and the recently described Gly2498Ser mutation in
the pore domain affecting IP3R2 function [126] is depicted in red.
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in planar lipid bilayers.
It must however be pointed out that a number of studies found a
rank-order of afﬁnities that is different from that mentioned above
[53,54]. Although this discrepancy has never been fully clariﬁed, it can
be assumed that variability in the experimental conditions (e.g. pH,
[Ca2+]) as well as in the state of the IP3Rs (e.g. redox state, phosphory-
lation state, associated proteins, existence of heterotetramers) could
explain this variability [1].
Taken together, most of the available evidence points to IP3R2 as
being the most sensitive IP3R isoform. This observation raises the
intriguing potential that IP3R2 can be active in the presence of basal,
resting IP3 levels.2.2. Regulation by cytosolic Ca2+
It has long been recognized that IP3R activity can be biphasically reg-
ulated by cytosolic Ca2+, meaning that a relatively low [Ca2+] (usually
less than 0.3 μM) potentiate IP3-induced Ca2+ release, while higher
[Ca2+] lead to an inhibition of the IP3R. Plotting IP3R activity against
[Ca2+] therefore leads to a typical bell-shaped curve. The original
observations were obtained in smooth muscle [55], neurons [56,57]
and oocytes [58], all tissues later shown to be particularly rich in
IP3R1. It was therefore a long-standing question whether this property
was uniquely related to this isoform or whether IP3R2 and IP3R3 shared
this property.
Although the stimulatory effect of Ca2+ on IP3R2 (and IP3R3) activity
has never been in doubt, the inhibitory action of a high [Ca2+] was not
always clearly observed. The group of Mignery published single-
channel data demonstrating that both IP3R2 endogenously expressed
in heart [51] or recombinantly expressed IP3R2 [59] displayed a much
broader bell-shaped dependence towards Ca2+, meaning that on the
one hand the stimulatory phase starts at a much lower [Ca2+] than for
IP3R1, and on the other hand that IP3R2 remains active at a [Ca2+]
already fully inhibiting IP3R1. In contrast to these reports, the group of
Bezprozvanny found quite similar (and narrow) [Ca2+] response curves
for each of the three IP3R isoforms heterologously expressed in Sf9
insect cells and investigated in planar lipid bilayers [60].
As will be further explained below (see Section 2.3), the sensitivity
of the IP3R2 towards Ca2+ is not dependent on the presence of ATP,
but the latter will increase the likelihood of IP3R2 being in an open
state at all [Ca2+] (Fig. 2).
Taken together, these results indicate that IP3R2, similarly to the
other IP3R isoforms, is regulated in a biphasic way by the cytosolic
[Ca2+], though that depending on the exact state of the receptor, differ-
ent sensitivities to Ca2+ can be observed.2.3. Regulation by ATP
2.3.1. Regulation of IP3R2 is distinct from other IP3Rs
Adenine nucleotides were recognized by early studies [61–68] as
important regulators of IP3-induced Ca2+ release, raising the attractive
possibility that channel activity could be ﬁne-tuned to match the
metabolic status of the cell. The diversity of cell types in which ATP
modulates IP3-induced Ca2+ release is consistent with a regulation af-
fecting all IP3R family members. However, two initial studies reported
that in contrast to IP3R1 and IP3R3, IP3R2 was not subject to modulation
by adenine nucleotides [48,52]. Speciﬁcally, studying individual mam-
malian isoforms reconstituted in planar lipid bilayers, Bezprozvanny
and colleagues reported that under conditions optimal for channel
activity IP3R2 had no requirement for ATP [52]. This observation was
independently conﬁrmed studying Ca2+ release from DT40 cells ex-
pressing a single IP3R isoform following genetic ablation of the other
familymembers [48]. These reports are, in hindsight, important because
they provide the ﬁrst indication that ATP regulation of IP3R2 was dis-
tinct from the other family members. A subsequent detailed analysis
of individual mammalian isoforms expressed in the DT40 TKO IP3R
null background conﬁrmed these earlier reports [69]. IP3R2 was indeed,
in contrast to other IP3R family members, insensitive to ATP at maximal
[IP3]. Nevertheless, it was demonstrated that IP3R2 activity,measured as
Ca2+ release, or at the single channel level in “on-nucleus” patch clamp
recordings, was markedly enhanced at sub-saturating [IP3] [69]. More-
over, the sensitivity of ATP regulation of IP3-induced Ca2+ release also
differed between individual isoforms under identical conditions with
IP3R2 being strikingly more sensitive than IP3R1 or IP3R3 (EC50 40 μM,
100 μM and 500 μM for IP3R2, IP3R1 and IP3R3 respectively) [69,70].
An issue posed by these data is the concentration range of ATP that
might be expected to dynamically regulate IP3R activity. In turn, this
raises the question whether modulation occurs at physiological levels
of nucleotides or is only relevant under pathological conditions when
ATP is depleted. Given the cellular levels of MgATP (~1 mM) and
“free” ATP3- and ATP4- (10–100 μM) the answer is fundamentally de-
pendent on the “species” of ATP that regulates IP3R channel activity.
Several studies have addressed this issue and have reached disparate
conclusions [67,71–73] and thus this important issue aswell as the con-
sequences of the high functional afﬁnity of IP3R2 remains to be resolved.2.3.2. Putative peptide motifs in IP3R2 responsible for ATP regulation
Modulation of IP3R activity is widely believed to occur by ATP bind-
ing to glycine-rich domains (Gly-Xaa-Gly-Xaa-Xaa-Gly), reminiscent of
Walker type A repeats, present in a number of proteins that utilize ATP
in a catalytic manner [74–77]. Consistent with this idea, a number of
studies using either photo-afﬁnity or ﬂuorescent ATP probes have
Fig. 2.Modulation of IP3R2 single-channel activity by IP3, Ca2+ and ATP. Representative single channel recordings of IP3R2 expressed in DT40 TKO cells using the “on-nucleus” conﬁgu-
ration of the patch-clamp technique. In A, channel activity was stimulated with a maximal [IP3] (10 μM) at the indicated [Ca2+] and [ATP] (10 μM, in blue; 5 mM, in black). The pooled
data in B reveal that channel activity stimulated bymaximal [IP3] ismodulated by [Ca2+] in a biphasicmanner and that this relationship is unaffected by increasing the [ATP]. In C, channel
activity was stimulatedwith a sub-maximal [IP3] (1 μM) at the indicated [Ca2+] and [ATP] (10 μM, in blue; 5mM, in black). The pooled data in D demonstrate thatwhile channel activity is
also biphasically regulated by [Ca2+] at sub-maximal [IP3], the maximally achievable open probability, at each [Ca2+], is, in contrast to what happens at a maximal [IP3], markedly poten-
tiated in the presence of a high [ATP]. Modiﬁed from [79], with permission.
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recombinant fragments harbouring these putative recognition sites
[69,75–77]. The primary sequence of IP3R2 contains one such motif,
Gly-Leu-Gly-Leu-Leu-Gly, spanning amino acids 1969-1974, which has
been termed the “ATPB” site (Fig. 1). Mutagenesis of three Gly residues
to Ala in the motif eliminated binding of ATP and nucleotide regulation
of Ca2+ release, conﬁrming the functional importance of theATPB site in
IP3R2 [69]. Moreover, in cells expressing IP3R2 with an ATP binding-
deﬁcient ATPB motif, the frequency and amplitude of B cell receptor-
activated Ca2+ oscillations were markedly reduced compared with
wild-type IP3R2, suggesting strongly that nucleotide regulation of
Ca2+ release is at least, constitutively required to shape cytosolic Ca2+
signals at physiologically relevant ATP levels [69]. Unexpectedly, muta-
tions of all knownWalker Amotifs in IP3R1 and IP3R3 failed to abrogate
nucleotide modulation [70]. The somewhat surprising conclusion is
therefore, that ATP regulation of IP3R1 and IP3R3 is independent of
known ATP-binding motifs, and thus the identity of molecular sites of
nucleotide regulation in these IP3R remains to be elucidated. Conse-
quently, the ATPB site in IP3R2 is unique as the only molecular locus
for regulation of IP3R familymembers by adenine nucleotides that is de-
ﬁned unequivocally.
2.3.3. Mechanism of ATP regulation of IP3R2
Several studies have investigated the biophysical basis for ATP regu-
lation of IP3R channel activity. In accordance with the singular features
of IP3R2 when compared with other family members, it also appears
that ATP regulates IP3R2 in a similarly distinctive manner. Using “on-
nucleus” patch clamp single channel recordings of both endogenous
Xenopus IP3R1 or rat IP3R1 expressed in DT40 TKO cells, elevating ATPlevels increased the channel open probability (Po) by modulating the
sensitivity of the channel to both activating and inhibitory [Ca2+],
essentially left-shifting the bell-shaped [Ca2+] versus Po relationship
at a given [IP3] [78,79].
In contrast, while IP3R2 displays an identical biphasic Ca2+ sensitiv-
itywhen exposed to saturating [IP3] (conditions inwhich IP3R2 is insen-
sitive to ATP), at low [IP3], the Ca2+ sensitivity of mouse IP3R2 was not
altered by increasing ATP [79]. Elevating ATP simply dramatically en-
hanced Po, resulting in a marked increase in activity. A detailed kinetic
analysis of the channel gating also indicated that IP3R2 displayed
“bursting” activity with properties distinct from IP3R1 (Fig. 2). Speciﬁ-
cally, with elevated ATP, the number of bursting episodes of relatively
constant duration was increased, while IP3R1 bursts simply lengthened
in time. By analogy to a gear change in a car, we have termed this the
transition from ‘park’ into a ‘drive’mode. Aminimal scheme to describe
the channel kinetics at sub-saturating [IP3] suggests that both channels
transition between single open and closed states during drive mode
with relatively constant kinetics and then are “parked” in a longer-
lived closed state in the interburst intervals [79]. In the case of the
IP3R1, increasing Ca2+ and ATP facilitates bursting by facilitating both
the transition out of the parked state and also by decreasing the likeli-
hood it will return to this state. In contrast, [Ca2+] does not inﬂuence
the time the IP3R2 spends in drive mode but simply destabilizes the
parked state to initiate activity (Fig. 3). Increasing ATP then appears to
markedly increase overall channel Po by prominently decreasing the
amount of time in the parked state [79]. This unique property results
in dissociation of the modulation of IP3R2 activity by ATP from the
[Ca2+] in its immediate environment and likely allows added ﬂexibility
for tuning Ca2+ signals to the needs of the cell.
Fig. 3. “Park and Drive” model for IP3R1 and IP3R2 gating. An increase in IP3R1 (A) and IP3R2 (B) channel activity in the presence of activating ligands is characterized by an increase in
channel “bursting”without altering the intraburst kinetics. The bursts have subtype speciﬁc characteristics. A gating scheme for both channels canminimally be described by three states;
one open state (in green) and two closed states (in red). Bursting activity is represented by rapid transitions between the open state (O) and a short-lived closed state (C1) representing the
“DriveMode” of the channel. In the interburst intervals, the channel is effectively “Parked” in a long-lived closed state (C2). For both IP3R1 (A) and IP3R2 (B) increasing the concentrations of
activating ligands solely alters the transition from C2 to C1. However, ligands both increase the likelihood that IP3R1 will leave the parked state to drive mode, as well as reciprocally
decreasing the chances itwill return to this state, thus extending the period of bursting (A). In the case of IP3R2, ligands only destabilize the parked state resulting in an increase in bursting
episodes of relatively constant duration (B).
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An important question exists as to how the distinct features of
individual IP3R subtypes are reﬂected in the overall characteristics of
Ca2+ release from heterotetrameric channels. Speciﬁcally, are the
properties simply a blended integration of the individual subtypes or
can a particular subtype dominate the overall characteristics? Studies
investigating ATP regulation of Ca2+ release in cells expressingmultiple
IP3R isoforms indicate that the latter possibility occurs, speciﬁcally
when IP3R2 is expressed. For example, the characteristics of ATP regula-
tion of IP3R2 (albeit the lack of regulation at saturating [IP3]) were ob-
served in DT40 cells engineered to express only IP3R2, or in cells
expressing both IP3R2 and IP3R1 or IP3R3 [48]. Similarly, in salivary
and pancreatic acinar cells [80,81], which natively express IP3R2 and
IP3R3 to approximately equal extents, the features of ATP regulation
precisely match those documented for IP3R2 stably expressed inisolation in either DT40 TKO [69] or in AR42J pancreatoma [80] cells
(i.e. absence of regulation at saturating [IP3] and EC50 for ATP ~40 μM).
Notably, similar experiments in pancreatic and parotid acinar cells
prepared from IP3R2 null animals revealed identical properties to
IP3R3 (i.e. regulation at all [IP3] and EC50 for ATP ~500 μM) [80,81]. Con-
versely, “rescue” experiments ectopically expressing IP3R2 in RINm5F
insulinoma cells which predominately express IP3R3, converted IP3R3
characteristics to IP3R2 [80]. While these data clearly indicate the
dominant inﬂuence of IP3R2 expression and are consistent with this
occurring as a function of heterotetramer formation, these data could
also formally be explained by an intermolecular interaction between
clusters of homotetrameric IP3R. This issue has recently been tackled
by generating tetrameric IP3R from concatenated IP3R dimers connected
by short ﬂexible linkers [82]. Expression of dimers results in the assem-
bly of tetramers where the subunit composition can be unequivocally
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properties of ATP regulation typical of channels assembled from their
respective monomeric parent subtype. Remarkably when heterodimers
of IP3R1 and IP3R2 were expressed, resulting in assembly of channels
consisting of equal numbers of IP3R1 and IP3R2 subunits, ATP regulation
was indistinguishable from IP3R2, thus recapitulating the dominant ef-
fects seen in cells expressing native receptors [82]. These data indicate
that IP3R2 in the context of a heterotetrameric channel exerts a domi-
nant inﬂuence. Further work is needed to establish the number of
monomers of IP3R2 necessary to exert this inﬂuence and whether
IP3R2 similarly is the principle monomer that dictates the overall chan-
nel properties when subjected to other forms of regulation.
2.4. Regulation by phosphorylation
Like for many other ion channels, phosphorylation/dephosphoryla-
tion reactions provide a versatile, reversible form of acute regulation
of IP3R activity. IP3Rs have been shown to be biochemical substrates
for numerous families of serine/threonine and tyrosine directed kinases.
In a more limited number of cases, a comprehensive documentation of
the phosphorylation event, including location of the substrate motif
and the subsequent functional consequences have been detailed.
These studies have largely focused on IP3R1 as a template. With some
notable exceptions, for example the AKT/PKB site conserved in the C-
termini of each IP3R [83,84], the amino acidmotifs subject to phosphor-
ylation events are not generally preserved between IP3R subtypes
(Fig. 1). Therefore, this form of regulation has the capacity to provide
modulation of activity in an IP3R sub-type speciﬁc manner. Below we
highlight reports that have speciﬁcally focused on regulation of IP3R2
activity. The interested reader is directed to Vanderheyden et al. [23]
and Betzenhauser and Yule [85] for detailed discussion of IP3R phos-
phorylation and its functional consequences.
2.4.1. Regulation of IP3R2 by protein kinase A (PKA)
Historically, perhaps themost exhaustive investigation of IP3Rmod-
ulation relates to PKA phosphorylation of IP3R1. Indeed, IP3R1was iden-
tiﬁed as a major brain phosphorylated substrate even prior to the
protein being appreciated as the receptor for IP3 [86]. Subsequent stud-
ies demonstrated that IP3R1 is phosphorylated at serine residues within
two canonical consensus motifs (Bas-Bas-Xaa-Ser/Thr, where Bas = a
basic residue) [87,88] and phosphorylation is associated with markedly
enhanced Ca2+ release [89,90]. To complete the strong case for IP3R1
being a functionally important PKA substrate, mutation of Ser1589 and
Ser1755 to non-phosphorylatable alanine residues completely abrogates
phosphate incorporation and the functional effects of PKA activation
[90–92]. However, while PKA activation in cells that predominately ex-
press IP3R2 such as hepatocytes, parotid acinar cells and AR42J similarly
results in enhanced Ca2+ release [93–95], the PKA substrate motifs
present in IP3R1 are not conserved in IP3R2 [5]. In addition, while PKA
activation results in IP3R2 phosphorylation, phosphate incorporation is
non-stoichiometric and indeed much reduced in comparison to IP3R1
[96]. Nevertheless, IP3R2 contains approximately 30 serine or threonine
residues, which constitute minimal PKA consensus motifs consisting of
basic residues preceding the phosphorylated amino acid at the -2 and
-3 positions (Bas-Bas-Xaa-Ser/Thr). Using an approach based on ex-
pressing consecutive domains of IP3R2 with N-terminal epitope tags, it
was shown that PKA could only speciﬁcally phosphorylate in vitro a
peptide fragment consisting of amino acids 920-1583 [97]. Mutation
of Ser937 to alanine (Ser937Ala) abrogated all phosphorylation of the
fragment, pinpointing this residue as the PKA target site (Fig. 1). Subse-
quently, it was shown that an antibody raised against phospho-Ser937
recognized IP3R2 after forskolin treatment in cells expressing IP3R2
but not cells expressing a mutant full-length receptor harbouring a
Ser937Ala mutation [97]. Notably, Ser937 was independently identiﬁed
as a phosphorylated residue in a proteomic screen of hepatocytes [98].
Importantly, PKA activation markedly potentiated IP3-induced Ca2+release in DT40 TKO cells expressing IP3R2 but not Ser937Ala IP3R2
thus establishing this motif as likely solely responsible for the PKA-
mediated phospho-regulation of IP3R2 [97]. The Ca2+ signalling ma-
chinery is a rich source of substrates responsible for cross-talk between
cAMP and Ca2+ signalling which ensure ﬁne-tuning of the Ca2+ signal
and appropriate activation of effectors [99]. PKA phosphorylation of
IP3R2 likely is an important site of this interaction in cells such as astro-
cytes, cardiac myocytes, hepatocytes and acinar cells that prominently
express this family member.
2.4.2. Regulation of IP3R2 by Ca
2+/calmodulin-dependent protein kinase II
(CaMKII)
CaMKII are a family of serine/threonine kinases assembled as either
homo- or heteromultimers derived from the products of four closely re-
lated genes [100]. As a Ca2+/calmodulin-regulated enzyme, this kinase
is an important primary effector of IP3R-induced Ca2+ release and ac-
cordingly plays prominent roles in regulating various signal transduc-
tion pathways including the translocation of transcription factors and
activity of ion channels [101,102]. Notably, IP3Rs are substrates for the
kinase, which provides a regulatory loop following Ca2+ release. Early
work suggested that IP3R1 was a substrate for CaMKII in vitro and that
the siteswere distinct from those phosphorylated by PKA [103], howev-
er the functional consequences were poorly deﬁned. Subsequently,
studies based largely on pharmacology, concluded that Ca2+ release
from Xenopus oocytes and HeLa cells was attenuated following CaMKII
activation [104,105]. More recently, a thorough characterization of the
molecular sites and functional consequences of the CaMKII-mediated
phopho-regulation of IP3R2 has been reported. Using a similar approach
to that used to identify PKA sites, the ability of CaMKII to phosphorylate
IP3R2 fragments in vitrowas assessed. It was initially demonstrated that
a candidate residue was present within a fragment encompassing the
initial 1078 amino acids [106] and further reﬁnement narrowed the po-
tential phosphor-acceptor residue to within residues 134-338 [107].
Subsequent mutagenesis of potential serines/threonine residues in
CaMKII consensus motifs (Ser/Thr-Xaa-Asp) within this region [107]
identiﬁed Ser150 as phosphorylated by CaMKII (Fig. 1). This site is con-
served in mammalian IP3R family members and ryanodine receptor
(RyR) 2, suggesting a common mode of regulation in these channels.
When incorporated in bilayers, CaMKII phosphorylation reduced the
Po of IP3R2 and this effect was reversed by the CaMKII inhibitor KN62.
Importantly, the reduced channel activity was absent in Ser150Ala
IP3R2, indicating that the site was functionally relevant [107]. Notably,
CaMKII colocalizes and interacts with IP3R2 in the nuclear envelope of
cardiac myocytes [106,108]. This interaction has been proposed to be
functional important for cardiac remodelling during hypertrophy
[109] (see Section 4).
2.4.3. Regulation of IP3R2 by protein kinase C (PKC)
Cerebellar IP3R was also initially identiﬁed as a substrate for PKC
with phosphorylation sites independent of those sites modiﬁed by
PKA [103]. Interestingly, however, it was demonstrated that phosphor-
ylation by PKCwas enhanced by prior PKA phosphorylation indicating a
potential additional layer of cross-talk between these prominent cellu-
lar signalling systems [110]. Similarly to CaMKII, because at least con-
ventional PKC family members are regulated by an elevation in Ca2+,
PKC phosphorylation provides a potential feedback loop to regulate
IP3R activity. To date however, the functional effects of PKC phosphory-
lation and the sites of phosphorylation are relatively poorly deﬁned. Un-
fortunately, despite the general appreciation of the amino acid motifs
that constitutes a PKC consensus sequence and the presence of multiple
such templates in IP3R, none have been experimentally deﬁned. Fur-
thermore, while PKC activation results in enhanced Ca2+ release from
liver nuclei, presumably reﬂecting IP3R1 and IP3R2 activity [111], Ca2+
release is inhibited in AR42J cells, which predominately express IP3R2
[112]. These disparate ﬁndings may reﬂect subtype-speciﬁc regulation
of IP3R given that the PKC consensus motif numbers and location are
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ation is that numerous proteins in the signalling pathway from plasma
membrane receptor occupation to the generation of Ca2+ signals are
substrates for PKC and thus caution must be taken in interpreting data
generated from indirectmeasurements of IP3R activity. Our own experi-
ence is that IP3R2 single channel activity recorded in either DT40 cell
nuclei or in DT40 plasma membranes was unaffected by phorbol ester
treatment or recombinant PKC exposure (Wagner, Chandrasekhar and
Yule; unpublished observations). These data might indicate that IP3R
is not a direct substrate for PKC. Yet, we cannot formally exclude the
possibility that a scaffolding or anchoring protein necessary for activity
is absent from theDT40 system.Hence, furtherwork is required to char-
acterize the impact of PKC on IP3R activity in general and on IP3R2 in
particular.
2.5. Other characteristics of IP3R2
All the characteristics discussed above (see Sections 2.1–2.4) have
been the subject of extensive investigations. There are however, a few
less studied properties, which nevertheless might be very interesting
for understanding the cellular function of IP3R2.
2.5.1. Regulation of IP3R2 by cAMP
Similarly to the other IP3R isoforms, many accessory proteins inter-
act with, andmodulate IP3R2 function. These proteins include regulato-
ry and structural proteins, many of whichwere also reported to interact
with IP3R1 and/or IP3R3 [1,2,14].
An interesting exception is the interaction described between IP3R2
and type 6 adenylate cyclase (AC6) [113]. In HEK 293 cells stably
transfected with the type I parathyroid hormone receptor, a complex
is formed between IP3R2, AC6 and Gαs [113,114]. This close association
facilitates an exquisite regulation of IP3R2 by cAMP, and in addition,
Ca2+ released through IP3R2 may control AC6 in a negative feedback
loop. Importantly, the regulation by cAMP does not require the canoni-
cal ATP-binding site or the activity of PKA. Moreover, although all IP3R
isoforms are potentially sensitive to cAMP, only IP3R2 has been un-
equivocally linked to a cAMP-producing enzyme (AC6) [114]. This
mechanism can be of great general importance, since it provides a
novel example of cross-talk between the cAMP- and the Ca2+-
dependent pathways.
2.5.2. Clustering and mobility of IP3R2
All IP3R isoforms, including IP3R2 [115] are known to cluster in an
agonist-dependent way [116] but a punctate distribution of IP3R2 has
also been observed for native IP3R2 [117] and heterologously expressed
IP3R2 [41] in resting cells. This property can be correlated to the higher
afﬁnity of IP3R2 for IP3 (see Section 2.1), whichmay allow the clustering
to occur at basal, resting [IP3]. Interestingly, also other differences in be-
haviour were found between the different IP3R isoforms. A recent study
performed in COS-7 cells conﬁrmed that heterologously expressed
IP3R2 showed a punctate distribution, in contrast to IP3R1 and IP3R3
that were uniformly distributed [118]. Moreover, IP3R2 appeared
much less mobile than either the other IP3R isoforms or than other pro-
teins involved in intracellular Ca2+ handling, such as RyR1 or sarco/
endoplasmic reticulum Ca2+ ATPase (SERCA) 1. In addition, its mobility
depended on its intracellular localization with the IP3R2 located in the
perinuclear region having the lowest mobility. As the IP3R2 has the
highest sensitivity to IP3 (see Section 2.1), its lesser mobility may deter-
mine the initiation sites for intracellular Ca2+ signals.
3. The function of IP3R2 in secretory cells
IP3R2 exhibits prominent expression in classical secretory cells
(Table 1), including exocrine cells of the pancreas [119–121], salivary
glands [81,120–123], lacrimal gland [124], olfactory glands [125], liver
[29], eccrine sweat glands [126] and the secretory epithelia of the biliarytree [127] and the intestine [18] and the goblet cells of the small intes-
tine [128]. A common feature of these epithelial cells is that they are
morphologically and functionally polarized to secrete ﬂuid and protein
across their apical pole into a lumen forming a duct. Notably, the Ca2+
signal is centrally important to the primary secretory function of these
cells by virtue of directly activating ion channels and the exocytotic ma-
chinery necessary for vectoral ﬂuid and protein secretion [129,130]. In
exocrine glands, IP3R2 and IP3R3 are expressed in approximately equal
numbers [12] and both familymembers are co-localized to a region im-
mediately below the apical plasma membrane [119,120]. This region
has been termed “the trigger zone” because Ca2+ signals are invariably
initiated in this region prior to the signal spreading as a Ca2+ wave
towards the basal aspects of the cell [131–133]. There appears to be sub-
stantial functional redundancy between IP3R2 and IP3R3 in exocrine
cells asmice null for either IP3R in isolation have no obvious phenotype.
However, compound knockouts of IP3R2 and IP3R3have severe exocrine
deﬁciency manifested as dry mouth [121], dry eye [124], pancreatic in-
sufﬁciency [121] and attenuatedmucus secretion [125]. As such, double
knockouts are born normally but demise soon after weaning [121]. In-
deed a detailed analysis of these mice have shown that Ca2+ signals in
pancreatic, salivary, lacrimal andmucus glands are essentially unaltered
in IP3R3 nullmice [121,124,125] and only reduced to amodest degree at
low [IP3] in IP3R2 nullmice [80,81,121,124,125]. These data suggest that
IP3R2 is not generally essential for overall exocrine function.
A possible exception to this idea has been highlighted by a recent
study, which investigated the cause of a severe congenital sweating de-
fect in a Pakistani family [126]. Ca2+ signalling is known to be important
for sweat secretion and both IP3R2 and IP3R3 are expressed in the secre-
tory cells of the sweat gland. A screen based on identifying regions of
autozygosity in the genome of afﬂicted individuals revealed a mutation
(Gly2498Ser) targeting an amino acid predicted to be critical to the func-
tion of the selectivity ﬁlter in the pore region of IP3R2. This mutation
rendered the channel completely inactive when expressed in DT40
TKO cells, thus potentially explaining the defect observed in the pa-
tients. Consistent with this idea, subsequent studies showed that mice
lacking IP3R2 exhibited a decreased ability to sweat although the effect
was more modest than observed in humans. The differences in severity
between the phenotype observed between mouse and human may
reﬂect the relative levels of these subtypes in mouse versus human. Al-
ternatively, the relativelymild phenotype in themousemight be related
solely to the knockout of IP3R2, reﬂecting some degree of compensation
by the residual IP3R3. In this scenario the more severe effect in human
could be due to the combined effect of ablation of IP3R2 pore function
and a possible dominant negative effect of the mutant IP3R2 when
incorporated into heterotetramers containing IP3R3.
The primary secretory function of hepatocytes is the secretion of bile
and changes in intracellular Ca2+ play important regulatory roles in this
process. Hepatocytes express predominantly IP3R2 (Table 1) with
smaller amounts of IP3R1 and virtually no IP3R3. However, in contrast
to exocrine acinar cells, each isoform exhibits a distinct sub-cellular lo-
calization and therefore the isoforms appear not to have redundant
functions. IP3R2 is enriched at the canalicular membrane, whereas
IP3R1 has a more uniform distribution throughout structures in the cy-
tosol [29]. Consistent with the sensitivity of IP3R2, agonist-induced
Ca2+ signalling is initiated through IP3R2 localized to the canalicular
membrane [29,134,135] and Ca2+ release through this isoform is
necessary for trafﬁcking of the bile salt export pump to the canalicular
membrane [134].4. The function of IP3R2 in the heart
As indicated (Table 1), cardiomyocytes are one of the cell types in
which IP3R2 are highly expressed. Both atria and ventricles express
IP3R2 [136] and consequently IP3R2 channels have been implicated in
both physiological and pathophysiological signalling in the heart.
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IP3R2 channels, together with IP3R1 channels, are critical for normal
cardiogenesis [137]. Consistent with this, IP3R2 and IP3R1 are
co-expressed in different parts of the embryonic heart, including atria,
ventricle and atrioventricular canal, and in different cell types, including
endothelial cells and cardiomyocytes, although timing differences in the
appearance of IP3R2 versus IP3R1 exist. IP3R1/IP3R2 double knockout
mice die in utero at embryonic stage E11.5 with major heart defects at
the level of the ventricles (thinmyocardial wall and poor trabeculation)
and the atrioventricular canal (reduced number of cells). These defects
were associatedwith a decrease in endocardial andmyocardial cell pro-
liferation. Furthermore, mesenchymal cells were lacking at the level of
the developing atrioventricular canal. The authors hypothesized that
this phenotype was due to the absence of IP3R-mediated Ca2+ signal-
ling, downstream of the activation of the Ca2+/calmodulin-dependent
phosphatase calcineurin and of the translocation of NFATc to the nucle-
us. Indeed, in an ex vivo epithelial-mesenchymal transition (EMT) assay,
the defect in EMT in atrioventricular explants derived from IP3R1/IP3R2
double knockout mice could be restored by transducing constitutively
active calcineurin. Moreover, the phenotype of these mice resem-
bled well the phenotypes of mice knockouts for calcineurin B
[138] or for NFATc3/NFATc4 [139]. Interestingly, the defect in en-
docardial cells could also be observed in developing zebraﬁsh ex-
posed to calcineurin inhibitors, such as FK506 or cyclosporine A.
Hence, from this study, it is clear that IP3R1 or IP3R2 channels are
needed for activating calcineurin/NFATc signalling and endocardial
cell proliferation in vertebrates. It is important to note that the
presence of either IP3R1 or IP3R2 is sufﬁcient to drive normal cardi-
ac development, indicating redundant functions for these channels
in this process. In addition to the cardiac crescent, or ﬁrst heart
ﬁeld, giving rise to a linear beating tube, there is a second source
of myocardial cells, which is termed the second heart ﬁeld. Howev-
er, with respect to the latter, it appears that there is a redundant
role for IP3R1 and IP3R3 [140]. IP3R1/IP3R3 double knockout mice
are characterized by hypoplasia of the outﬂow tract and the primi-
tive right ventricle at E8.5-9.5, probably due to a defective Mef2c-
Smyd1 transcriptional pathway.
At the functional level, IP3Rswere ﬁrst shown to impact contractility
and arrhythmias. Atrial myocytes express much higher levels of IP3R2
than ventricular myocytes [136]. They are activated in response to ele-
vated extracellular agonist concentrations, e.g. after ischaemia or during
disease. Endothelin-1-induced IP3R activation promotes the inotropy
and the occurrence of arrhythmic events in atrial myocytes [141,142].
While in basal conditions, the cardiac function of IP3R2 knockout mice
was similar to one of wild-type mice, the positive inotropic effect and
the arrhythmic events induced by endothelin-1 were absent in IP3R2
knockout mice [143]. Hence, the presence of IP3R2 appears to be not
essential for the normal functioning of the rodent heart, which is in
line with the normal phenotype of the IP3R2 knockout mice generated
by Chen and co-workers [143] and by Mikoshiba and co-workers
[121].
In the ventricle, far fewer IP3Rs are present but may still contribute to
Ca2+ regulation under baseline conditions [144–147]. Moreover, a study
by Roderick and co-workers revealed that increased IP3R2-mediated
Ca2+ signalling, in response to enhanced IP3 signalling, is responsible
for inducing hypertrophic pathways after prolonged endothelin-1 expo-
sure of neonatal or adult rat ventricular cardiomyocytes [148].
Endothelin-1 triggered the expression of atrial natriuretic factor (ANF),
a marker for hypertrophy. Endothelin-1-induced hypertrophy was inde-
pendent of excitation-contraction coupling, but required IP3 signalling
and downstream IP3R-mediated Ca2+ release. The latter occurred in the
perinuclear region, but not in the cytosol, while Ca2+ transients linked
to excitation-contraction coupling occurred throughout the cardiomyo-
cyte. Speciﬁcally buffering nuclear Ca2+ by nuclear-targeted calbindin
prevented endothelin-1-induced ANF expression. The nuclear Ca2+ sig-
nal was mediated by IP3R2 channels, which were enriched in theperinuclear region and led to the activation of calcineurin and down-
stream NFATc1, which accumulated in the nucleus.
The IP3R/calcineurin/NFATc1 hyperactivity also seems to be opera-
tive in response to prolongedβ-adrenergic signalling, which occurs dur-
ing workload-induced cardiac hypertrophy via enhanced excitation-
contraction coupling. Interestingly, this model led to increased
endothelin-1 signalling. This involved the release of endothelin-1 and
autocrine/paracrine-mediated hyperactivation of its receptor (ETAR),
thereby triggering downstream IP3 signalling and Ca2+-dependent cal-
cineurin activation. In hypertrophic cardiomyocytes (e.g. derived from
spontaneous hypertrophic rats or from aortic-banded mice), IP3R2 not
only played a role in the nucleus, where its hyperactivation via in-
creased IP3 signalling downstream of ETAR led to calcineurin/NFATc1
activation andANF expression, but also becameupregulated in the junc-
tional sarcoplasmic reticulum [146]. Here, localization of IP3R2 coincides
with RyR2 channels, thereby augmenting Ca2+ transients associated
with excitation-contraction coupling or endothelin-1 exposure. As a
consequence, the IP3R2-mediated Ca2+ rise during diastole may
activate or sensitize RyR2 channels, resulting in spontaneous extra-
systolic Ca2+-release events and the occurrence of arrhythmias [147].
This increased “extra-nuclear” expression of IP3R2 was also found in
human heart samples derived from patients with heart failure after
ischemic dilated cardiomyopathy [146].
The upregulation of IP3R2 channels during cardiac hypertrophy was
mediated via a dynamic and Ca2+-dependent regulation of miRNA-
133a [149]. In normal physiological conditions, miRNA-133a expression
is highly expressed in cardiomyocytes, thereby targeting the 3’ untrans-
lated region of the IP3R2mRNA. As a consequencemiRNA-133a reduces
the basal expression of IP3R2 and thereby avoids hypertrophy or
arrhythmias resulting fromexcessive Ca2+ signalling. Interestingly, lim-
iting the expression ofmiRNA-133a using an antagomir led to hypertro-
phic signalling (evident from the increased ANF expression), whichwas
dependent on IP3-induced Ca2+ release, since degrading IP3 using IP3
5-phosphatase limited the increase of ANF by miR-133a antagomir.
The role of miR-133a in controlling IP3R2 expression and the
initiation of hypertrophic markers was found both ex vivo and in vivo.
In isolated, hypertrophic cardiomyocytes from spontaneous hyperten-
sive rats, IP3R2 levels were elevated, while miRNA-133a was downreg-
ulated [149]. Overexpression of miRNA-133a in these hypertrophic
cardiomyocytes reduced ANF expression to levels similar as control
cardiomyocytes. In addition, in vivo application of miRNA-133a
antagomir caused IP3R2 upregulation and hypertrophic signalling. In-
terestingly, increased IP3-induced Ca2+ release was also involved in
the decreased miRNA-133a expression in hypertrophic models. Indeed,
lowering IP3 signalling by IP3 5-phosphatase transduction blunted the
endothelin-1-induced decrease inmiRNA-133a and the concomitant in-
crease in IP3R2 protein levels. Collectively, these ﬁndings indicate that
during pathophysiological conditions associated with increased
endothelin-1, increased IP3 signalling can lead to downregulation of
miRNA-133a. The latter will lead to upregulation of IP3R2 protein levels,
thereby further driving the downregulation of miRNA-133a by boosting
IP3-induced IP3R2-mediated Ca2+ signalling. This perpetual feedback
cyclewill establish a new signallingnetwork that favours the expression
of hypertrophic genes like ANF (via hyperactivation of calcineurin/
NFATc1) and the occurrence of arrhythmic events.
The mechanism by which IP3-induced Ca2+ release controls
miRNA-133a expression seems to involve transcription factors like
the serum response factor (SRF), which is negatively regulated by
the homeodomain-only protein. SRF induces miRNA-133a expres-
sion and subsequent IP3R2 downregulation. However, during hyper-
trophy, IP3-induced Ca2+ release may increase homeodomain-only
protein expression, thereby recruiting class I histone deacetylase
(HDAC) and limiting transcriptional activity of SRF.
The importance of IP3 signalling and IP3R2 has also been elegantly
addressed byMolkentin and co-workers by the generation of transgenic
mice overexpressing an IP3 sponge, which represents a mutated, high-
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Ca2+ release by trapping IP3), or overexpressing IP3R2 (to boost IP3-
induced Ca2+ release) in cardiomyocytes [150]. Mice overexpressing
the IP3 sponge displayed reduced cardiac hypertrophy in response to
chronic β-adrenergic stimulation and angiotensin II stimulation. In con-
trast, IP3R2-overexpressing mice displayed only a mild cardiac hyper-
trophic phenotype under basal conditions. However, when cardiac
hypertrophy was induced (e.g. using transverse aortic constriction,
chronic β-adrenergic stimulation or overexpression of Gαq, an up-
stream phospholipase C activator) mice expressing high IP3R2 levels
demonstrated increased hypertrophic responses. Under these condi-
tions, mice expressing low levels of IP3R2 (except for transverse aortic
constriction) also displayed enhanced cardiac hypertrophy. Moreover,
IP3R2 channels,which already display high sensitivity to IP3,may be fur-
ther sensitized by increased PKA signalling downstreamof β-adrenergic
receptor stimulation leading to hyperphosphorylation of IP3R2 at Ser937
[97] (see Section 2.4.1). The increased sensitivity of IP3R2-expressing
mice to cardiac hypertrophy-inducing conditions could be linked to in-
creased calcineurin and NFAT signalling. Consistent with this, the aug-
mented cardiac hypertrophic response in IP3R2-overexpressing mice
were completely blunted when these mice were crossed with calcine-
urin B-knockout mice, indicating an essential role of calcineurin/NFAT
signalling in response to hyperactive IP3R2-mediated Ca2+ signalling.
While from the above studies, calcineurin emerged as the downstream
target of increased IP3R-mediated Ca2+ signalling, it is important to
note that also nuclear CaMKIIδ has been implicated in altered transcrip-
tion in response to cardiac hypertrophic endothelin-1 signalling [109].
Increased IP3 signalling in response to endothelin-1 triggers a unique
nuclear Ca2+ signalling that does not occur during excitation-
contraction coupling but activates CaMKII, which together with protein
kinase D results in the phosphorylation and nuclear export of class II
HDAC5, a transcriptional repressor. In healthy conditions, nuclear
HDAC5 forms a complex with the transcription factor MEF2, thereby
preventing the transcription of hypertrophic genes. In hypertrophic
conditions, HDAC5 is exported from the nucleus, leading to de-
repression of MEF2 and the induction of hypertrophic genes. Interest-
ingly, blocking IP3Rs using chemicals like 2-aminoethoxydiphenyl
borate or using IP3R2-knockout mice, prevents the nuclear export of
HDAC5 and subsequent activation of the hypertrophic transcription
program.
All these studies are consistentwith a critical role for Ca2+ signalling
via IP3R2 in cardiac hypertrophy, being in the nucleus and required for
driving transcription of hypertrophic genes and in the junctional sarco-
plasmic reticulumbeing responsible for driving extra-systolic Ca2+ rises
and contractions.Moreover, these studies all support the concept of dis-
tinct Ca2+ signalling compartments in cardiomyocytes, either in the cy-
tosol during physiological excitation-contraction coupling driven by
RyR2 channels or in the nucleus during pathophysiological hypertro-
phic signalling driven by IP3 and IP3R2 channels [151].
5. The role of IP3R2 in cell death and in senescence
Over the last 20 years, IP3R channels have emerged as key regulators
that control cell death and survival in a variety of cellular systems [14,
152–154]. T cells deﬁcient in IP3R1 are resistant to a variety of apoptotic
triggers, including chemical stimuli, like corticoids, and biological stim-
uli, including excessive T-cell receptor stimulation and exposure to Fas
ligand [155]. Interestingly, susceptibility to T-cell receptor stimulation
could be restored by artiﬁcially rising the cytosolic [Ca2+] using the
SERCA inhibitor, thapsigargin. Also, a role for IP3R3 has emerged in
pro-apoptotic Ca2+ signalling [156], because some studies proposed
that this channel may be preferentially located in the mitochondrial
ER-associated membranes. As such, IP3R3 channels are thought to be
part of the “quasi-synaptic” Ca2+-transport complex between the ER
Ca2+ stores and the mitochondria that can involve IP3Rs, GRP75 and
VDAC1 [157,158]. Nevertheless, it is becoming increasingly clear thatall IP3R isoforms participate in apoptotic Ca2+ signalling and/or inﬂu-
ence the susceptibility of cells towards apoptotic stimuli. This can
mean two things: i) not only IP3R3, but also IP3R1 and IP3R2 channels
can be part of the ER-mitochondrial junction complexes, and ii) not
only direct Ca2+ transfer into the mitochondria, but also other down-
stream Ca2+-dependent signalling pathways participate in triggering
mitochondrial outer membrane permeabilization, the point-of-no-
return in apoptosis. Furthermore, it is important to emphasize that a
complex interaction exists between IP3Rs and proteins from the B-cell
lymphoma (Bcl)-2 family involved in the control of apoptosis, whereby
several interaction sites for such proteins have already been identiﬁed
on the IP3R [159–162].
IP3R-mediated Ca2+ release can lead to calcineurin activation,which
dephosphorylates the pro-apoptotic “sensitizer” BH3-only protein, Bad
[163,164]. Phosphorylated Bad is neutralized due to its scaffolding
with 14-3-3 proteins and therefore it cannot form a complex with
anti-apoptotic Bcl-Xl [165]. Dephosphorylation of Bad by calcineurin,
e.g. in response to increases in cytosolic [Ca2+] mediated by IP3Rs
[164], results in Bad release from 14-3-3 proteins and its translocation
from the cytosol to the mitochondrial membranes. Here, it can bind to
and inhibit anti-apoptotic Bcl-Xl proteins [163], thereby displacing
Bim/tBid, which then can activate Bax/Bak and induce apoptosis.
These data indicate that dampening the IP3R-mediated Ca2+ rise,
either by lowering IP3R levels or altering the IP3R-expression proﬁle,
by inhibiting the Ca2+-ﬂux properties of IP3Rs, or by lowering the ER
Ca2+ content, which decreases the driving force for Ca2+ release into
the cytosol upon IP3R activation, will be cytoprotective [162]. Not sur-
prisingly, different pro-survival signalling mechanisms, which are
often oncogenic, appear to have exploited this concept to promote cell
survival, including the survival of malignant or altered cells. In many
cases, different mechanisms can be simultaneously operative. For in-
stance, oncogenic KRAS mutations appear to switch the expression
from IP3R3 into IP3R1 and to lower the ER Ca2+-store content, together
suppressing agonist-induced Ca2+ release and mitochondrial Ca2+
accumulation and thus protecting cells against menadione exposure
[166]. AKT/PKB phosphorylates all three IP3R isoforms, thereby sup-
pressing their pro-apoptotic Ca2+-release function [84,156]. Thismech-
anism is also exploited by tumour suppressors like the promyelocytic
leukemia protein, which enhance IP3R3 activity by counteracting PKB-
mediated IP3R3 phosphorylation [167]. Other survival/anti-apoptotic
proteins, like Bcl-2, have been reported to lower ER Ca2+ store-
content by sensitizing IP3Rs to basal IP3 levels and to directly suppress
IP3R-mediated Ca2+ release, thereby preventing toxic mitochondrial
Ca2+ overload [168]. Evidently, thesemechanisms will also result in re-
duced calcineurin activation, thereby limiting Bad dephosphorylation
and its subsequent inhibitory effects on the anti-apoptotic Bcl-2
proteins.
Whilemost studies have addressed the role of IP3R1 and IP3R3 chan-
nels in apoptosis, there is emerging evidence that IP3R2 channels play a
crucial role inmediating pro-apoptotic Ca2+ signalling. Deﬁnitely, IP3R2
with its high sensitivity to IP3 (see Section 2.1) may actually be a very
critical regulator of cell survival versus cell demise by rendering cells
sensitive to basal IP3 signalling. The role of IP3R2 in cell death has
been elucidated in different studies and using different approaches.
First of all, there is evidence that cell death triggered by cellular ex-
posure to cytotoxic compounds or agents that induce oxidative stress
has been associated with an increase in IP3R2 levels and activity.
lncreasing oxidative stress in a neuronal cell line exposed to sub-lethal
concentrations of tert-butyl hydroperoxide-mediated oxidative stress
led to prominent upregulation of IP3R2 mRNA and protein levels,
while IP3R1 and IP3R3-expression levels remained unaltered [38].
Consistent with elevated IP3R expression levels, Ca2+ release from the
nucleoplasm in response to a cell-permeable IP3 ester was strongly po-
tentiated in tert-butyl hydroperoxide-treated cells. Also, the nephrotox-
ic compound uranyl acetate has been shown to increase IP3R2 mRNA
and protein levels in human epithelial kidney cells, thereby increasing
2001T. Vervloessem et al. / Biochimica et Biophysica Acta 1853 (2015) 1992–2005the basal cytosolic [Ca2+] and apoptosis levels [169]. Similar ﬁndings
have been reported in HeLa cells exposed to fast H2S donors, although
in this case IP3R1 expression levels were also increased [170]. Interest-
ingly, IP3Rs may also be directly affected by reactive oxygen species
(ROS) [171]. In intact DT40 cells, superoxide anions caused Ca2+ release
from the ER, likely via a mechanism that sensitizes IP3Rs to basal levels
of IP3 signalling. In these DT40 cells, the presence of IP3R2 and IP3R1 iso-
forms, but not of IP3R3, was required for superoxide anion-induced
[Ca2+] rise in the cytosol.
The role of IP3R2 channels in apoptotic Ca2+ signalling was also
identiﬁed in B-cell cancer cells, in particular in a subset of “primed to
death” diffuse large B-cell lymphoma cell lines [172]. Cells expressing
high IP3R2 levels seem “addicted” to the presence and recruitment of
anti-apoptotic Bcl-2 proteins at the ER and especially in the IP3R protein
complex [173]. By interacting via its BH4 domain with the modulatory
and transducing domain of the IP3Rs, Bcl-2 inhibits IP3-induced Ca2+ re-
lease [174–176]. The binding site for the BH4 domain of Bcl-2 (Fig. 1)
has been identiﬁed [175] and is conserved between the three IP3R
isoforms [177]. Importantly, a peptide tool designed to disrupt IP3R/
Bcl-2-complexes by targeting Bcl-2’s BH4 domain (see [175–178]) was
very effective in inducing intracellular Ca2+ overload and provoking
cell death in DL-BCL cells that express high levels of IP3R2, like
SU-DHL-4 cells [172]. In contrast, cells that expressed very low levels
of IP3R2were virtually resistant to this peptide tool. The apoptotic resis-
tance of these cells to this peptide was not due to a general defect in the
initiation or execution of apoptosis, since staurosporine or BH3-mimetic
drugs were very effective in these cells. We hypothesize that anti-
apoptotic Bcl-2 is required at the ER to associate with the IP3R2 to
prevent its hyperactivity in response to the ongoing IP3 signalling
downstream of the B-cell receptor [173]. It remains to be elucidated
whether these ﬁndings translate into primary B-cell cancer cells. In
any case, disrupting IP3R/Bcl-2 complexes results in excessive Ca2+-
signalling patterns and apoptotic cell death in primary peripheral
mononuclear blood cells (mainly B cells) isolated from chronic lympho-
cytic leukaemia patients [179]. Remarkably, a gene expression proﬁle
analysis using the GeneSapiensmicroarray database revealed an upreg-
ulation of IP3R2 at the mRNA level in chronic lymphocytic leukaemia
samples [173].
IP3R2 channels are not only implicated in apoptosis but also play a
role in cellular senescence. Stable cell cycle arrest is a key feature of
cellular senescence, which is activated in response to cellular stress.
Factors include oncogenic stress following loss of PTEN function, DNA
damage or telomere attrition, oxidative stress and replicative stress
[180]. The arrest in proliferation depends on themajor tumour suppres-
sor pathways involving p53/p21 and p16/Rb [180,181]. At the physio-
logical level, cellular senescence contributes to ageing at the level of
the organism [182]. However, cellular senescence can also function as
an important “health keeper” ﬁghting pathophysiological conditions
associatedwith oncogenic stress [183,184]. As such, cellular senescence,
in addition to apoptosis, is one of the pathways that counteract cancer
cell initiation and tumour development [185,186]. For instance, in pre-
malignant hepatocytes, senescence led to the secretion of chemo- and
cytokines, resulting in their clearance by CD4+ T cells [187]. Loss of im-
mune surveillance caused the progression of the pre-malignant hepato-
cytes into hepatocellular carcinomas. Recently, Wiel et al. [188]
performed an elegant shRNA-based screen to identify which “loss-of-
function” genes can cause escape from oncogene-induced senescence
in immortalized human mammary epithelial cells (HEC). Interestingly,
the gene coding for IP3R2 was identiﬁed as a prominent modulator of
this form of senescence. These ﬁndings correlated with an analysis per-
formed by the authors using the Oncomine database, which indicated
that many malignant tumours displayed a decrease in IP3R2 mRNA
levels. IP3R2 shRNAs alleviated the growth arrest in HEC exposed to on-
cogenic stress. Prolonged incubation of these cells with cell-permeable
IP3 repressed cell growth and induced pre-mature senescence. Onco-
genic stress-induced senescence led to an increase in the Ca2+accumulation in the mitochondria, a process that did not occur in the
IP3R2 shRNA-treated cells, and also boosted IP3-induced mitochondrial
Ca2+ uptake. This mitochondrial Ca2+ uptake was proposed to be re-
sponsible for the decrease in mitochondrial potential observed during
oncogene-induced senescence, because shRNA against the IP3R2 or
against the mitochondrial Ca2+ uniporter prevented this decline in
mitochondrial potential. Interestingly, chemical induction of mitochon-
drial depolarization blocked cell growth and induced pre-mature senes-
cence. The role of IP3R2 and of the subsequent mitochondrial Ca2+
accumulation was linked to an increase in ROS production, since anti-
oxidants promoted oncogene-induced senescence escape. Finally,
these concepts may not be limited to oncogene-induced senescence,
but may also be applicable in models of replicative senescence. IP3R2
knockdown counteracted the increase in mitochondrial Ca2+ and the
decline in mitochondrial potential observed during replicative
senescence, thereby delaying the occurrence of senescence in these
models.
6. Conclusions
IP3R2 is characterized by a number of important and speciﬁc proper-
ties, including, but not limited to, its high sensitivity to IP3 and ATP.
Other properties such as its regulation by protein kinases, its interaction
with adenylate cyclase to couple to cAMP production, its ability to re-
cruit associated proteins and its low mobility in the ER, remain
underexplored. At the functional level, it is clear that IP3R2 is not only
important for regulating secretion, but also is implicated in health and
disease, including prominent roles in cardiac function and tumour
growth. The available evidence indicates that tumour cells either down-
regulate IP3R2 expression or dampen its activity via Bcl-2, since IP3R2
can promote senescence and/or apoptosis. It is now anticipated that fur-
ther research will elucidate additional important functions of IP3R2 in
other tissues and organs and further that developing tools speciﬁcally
targeting or impacting IP3R2 will allow modulating its function in dis-
ease states.
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